South Korea includes data exclusivity period for paediatric drugs approved abroad

Home/Policies & Legislation | Posted 10/09/2021 post-comment0 Post your comment

As of 5 May 2021, South Korea has updated the re-examination periods for post-marketing surveillance (PMS) of approved drugs. This now includes a four-year re-examination period for PMS that can now be granted for paediatric drugs approved based on both ‘domestic’ and ‘foreign’ clinical trials. 

71 MD002166

The South Korean re-examination system provides similar protection to data exclusivity in other countries and hence can be described as a de facto data exclusivity period for new drugs and certain prescription drugs.

Under the South Korean system, the re-examination period runs from the time of marketing approval and varies depending on certain criteria. In all but two scenarios, generics companies seeking marketing approval must submit their own safety and efficacy data equivalent to or exceeding the scope of the original approval holder’s data. The exempted scenarios are where the generics company has permission to use data from the original approval holder, or when an application is filed on the condition that the drug product will be approved after expiration of the re-examination period.

As such, during the re-examination period, generics companies cannot rely on the original approval holder’s data to obtain regulatory approval for their product and re-examination acts much like data exclusivity. After the PMS period, it is not necessary for generics companies to submit safety and efficacy data for marketing approval of a generic drug product.

The re-examination period varies from four to 11 years, depending on the type of drug application. The four-year period applies to ‘New Indication’ drugs, identical to those already authorized in terms of active ingredient(s) and administration route(s), but having different indication(s) included, or ‘Other’ drugs determined under the consideration of the Korean Ministry of Food and Drug Safety (MFDS). A six-year re-examination period can be granted for incrementally modified drugs, such those that have a new combination or new administration route. Some drug types such as orphan drugs may be exempted from the re-examination period.

Related articles
Opportunities for generics with Korean patent expires in 2021

South Korean guidelines for biosimilars


The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Conocimiento y percepciones de la denominación de biosimilares en EE. UU.

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Conocimiento y percepciones de la denominación de biosimilares en EE. UU.

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
First drugs for Medicare price negotiation selected
34 AA010660
Home/Policies & Legislation Posted 22/09/2023
Updated Biosimilar Red Tape Elimination Act introduced by Senator Lee
Interchangeability V18K30
Home/Policies & Legislation Posted 25/08/2023
Inflation Reduction Act explained
Regulation V13H16
Home/Policies & Legislation Posted 24/07/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010